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investigate the cost-effectiveness of including HPV vaccination in the preventive strat-
egy of cervical cancer. METHODS: We developed an interactive Markov model based 
on modeling disease progression. Data on prevalences, incidences, test characteristics, 
efﬁ cacy of vaccination and of cancer treatments, and quality of life of cervical cancer 
patients were taken from the scientiﬁ c literature. Data on the costs of screening and 
of cancer treatments were provided by the Hungarian National Health Fund. We 
applied 5% discount rate for both cost and utility values. The effect of herd immunity 
was taken into account in the model. GDP PPP exchange rate in 2009 was employed 
to convert local currency to EUR (1 EUR = 158 HUF). RESULTS: We analyzed the 
cost-effectiveness of different scenarios. In case of the most likely scenario to come 
through—vaccination at age 12, coverage 80%, vaccine effectiveness against 
HPV16/18 (responsible for 72% of cervical cancers caused by HPV) being 95%, 
vaccine is efﬁ cient for at least 20 years, the effectiveness of the screening program is 
not improved radically—the ICER for vaccination was c49,587/QALY compared to 
no screening. CONCLUSIONS: As disease burden of cervical cancer is high in 
Hungary, including HPV vaccination in the preventive strategy of cervical cancer 
would result in a cost-effectiveness ratio below the implicit upper threshold (3× GDP/
capita = c49,986 in PPP).
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OBJECTIVES: Bevacizumab in combination with platinum-based chemotherapy 
improves progression-free survival (PFS) over chemotherapy alone in advanced or 
metastatic NSCLC. The aim of this analysis was to assess potential cost savings for 
society derived from the clinical beneﬁ ts of bevacizumab-based therapy in metastatic 
NSCLC patients returning to work in France. METHODS: Indirect cost calculation 
was performed using human capital approach in the population of progression free 
metastatic NSCLC patients. Clinical outcomes in terms of PFS from the two bevaci-
zumab phase III trials (Reck et al. 2009, Sandler et al. 2006) were applied to the 
incidence cases of nonsquamous metastatic NSCLC patients in France, taking into 
account only age groups eligible to work. Clinical experts were consulted to estimate 
the percentage of PFS patients who return to work after the induction phase. It was 
estimated that 20% of PFS patients, below 55 years of age and with performance 
status 0–1 would maintain their prior employment status (60% part time, 40% full 
time). Cost savings were analyzed for 1 year and 1.5 year time horizons applying 
French labor costs. RESULTS: Indirect cost savings per patient returning to work were 
c21,667 at year 1 and c39,001 at year 1.5. a change in employment pattern (40% 
part time, 60% full time) led to an approximate 14% increase of savings for both 
time horizons (c24,763 at year 1 and c44,573 at year 1.5). a 10% alteration of labor 
cost in either direction resulted in cost savings that were 10% higher/lower. CON-
CLUSIONS: Bevacizumab-based therapy could result in considerable cost savings in 
progression-free NSCLC patients. This societal economic beneﬁ t adds to the patients’ 
clinical beneﬁ t of increased survival outcomes.
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OBJECTIVES: First-line treatment of advanced or metastatic NSCLC patients with 
bevacizumab demonstrated signiﬁ cantly improved progression-free survival (PFS) when 
added to platinum-based chemotherapy (Reck 2009; Sandler 2006). The aim of this 
analysis was to investigate whether this clinical beneﬁ t would translate into cost savings 
due to reduced productivity losses in metastatic NSCLC patients who return to work 
while treated with bevacizumab-based therapy in Germany. METHODS: Potential cost 
savings were calculated on the basis of reduced productivity losses for patients returning 
back to work during PFS periods of 1 and/or 1.5 years, applying the human capital 
approach. The percentage of progression-free patients with ECOG performance status 
0 and 1 was derived from the two bevacizumab phase III trials. Epidemiologic data as 
well as country-speciﬁ c employment rates were applied stepwise to estimate the meta-
static NSCLC patient population eligible to work and employed at diagnosis. It was 
assumed that 20% of progression-free patients would return to work after the induction 
phase while maintaining their prior employment status (40% full time). Cost savings 
related to productivity losses were calculated by applying German labor cost data to the 
derived population of interest. Results were weighted according to prescribing patterns 
of bevacizumab combination regimens (bevacizumab/cisplatin/gemcitabine or bevaci-
zumab/carboplatin/paclitaxel). Sensitivity analyses were performed for employment pat-
terns and labor cost. RESULTS: Mean cost savings were c21,171 at year 1 and c38,107 
at year 1.5 per progression-free patient returning to work in Germany. a change in 
employment pattern (60% full time) led to an approximate 14% increase of savings for 
both time horizons (c24,195 at year 1 and c43,551 at year 1.5). a 10% alteration of 
labor cost in either direction resulted in cost savings that were 10% higher/lower. 
CONCLUSIONS: In addition to its PFS beneﬁ ts bevacizumab-based therapy could result 
in considerable cost savings in progression free metastatic NSCLC patients.
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OBJECTIVES: Novel treatment options for NSCLC patients were shown to improve 
survival outcomes. Thus, it is of interest whether published evidence can be found on 
work productivity and employment consequences for this patient group and their 
informal caregivers, and on respective indirect cost data. METHODS: A systematic 
literature search from 1990 onward was performed using 19 bibliographic databases 
available via DIMDI (German Institute of Medical Documentation and Information), 
supplemented by searches for other publicly available sources such as abstracts at 
major health economic and clinical conferences, HTAs, and further gray literature. 
RESULTS: So far, published indirect cost data are elusive and rather limited to overall 
lung cancer. In lung cancer, indirect cost accounted for the major portion of total 
estimated cost, e.g., for Germany 78% (Ruff 2000) to 89% (Weißﬂ og 2001). Indirect 
costs per case seem to increase with stage. In an Australian study, overall stage IV 
lung cancer patients had direct and indirect costs that were 19% higher than the 
average (Bishop 2009). The only indirect cost information on advanced NSCLC was 
reported by Romanus (2008) for the United States (mean wage loss per newly diag-
nosed end-stage IV NSCLC patient was $1697 [$126–$3371] in the ﬁ rst few months 
after diagnosis) and by Perrone (2004) for Italy (mean productivity loss per patient 
of c60,263). Employment rates of NSCLC patients were reported to be about 13% 
of NSCLC stage IIIb or IV, treated with 2nd line chemotherapy in Italy (Gridelli 2007). 
In the same population, the informal care given by the principal caregiver was the 
main assistance cost item with average 3-month cost of c2368 representing 74% of 
total assistance cost. CONCLUSIONS: The indirect cost burden of NSCLC has 
scarcely been assessed so far and needs further quantitative investigation, particularly 
in view of the use of new treatment options.
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OBJECTIVES: Bevacizumab-based therapy as ﬁ rst-line treatment of advanced or 
metastatic NSCLC is associated with longer progression-free survival (PFS) when 
compared with chemotherapy alone (Sandler et al. 2006; Reck et al. 2009). This study 
analyzes the implications of the clinical beneﬁ ts of bevacizumab-based treatment for 
the societal costs in Spain. METHODS: Clinical inputs (PFS) were obtained from two 
clinical trials (E4599 and AVAiL) comparing a bevacizumab regimen (combined with 
carboplatin/paclitaxel or cisplatin/gemcitabine) with chemotherapy alone. Percentage 
of patients returning to work was estimated as 20% of all progression-free patients 
with ECOG performance status 0–1 in the age of ≤55 years. PFS percentage was 
applied to the incidence estimation for nonsquamous metastatic NSCLC in Spain after 
applying speciﬁ c employment rate. Indirect costs were calculated using the human 
capital approach. Spanish labor costs available at EUROSTAT were applied after 
inﬂ ating to 2009 values. Employment patterns were suggested by the clinical experts 
(full time/part time), and were applied to the estimation of patients returning to work. 
Time frames for the calculations were 12 months and 18 months. RESULTS: Average 
cost saving per progression-free patient was c12,401 at 12 months and c22,322 at 18 
months. Sensitivity analysis on changes in employment patterns from 40% full 
time/60% part time to 60% full time/40% part time increased cost savings per patient 
to c14,173 and c25,511 at 12 and 18 months, respectively. CONCLUSIONS: Treat-
ment with bevacizumab-based therapy results in the reduction of productivity losses 
due to improved clinical beneﬁ ts and hereby leads to considerable societal cost savings.
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OBJECTIVES: The high societal cost of lung cancer derives mostly from productivity 
losses associated with premature retirement and premature mortality (Weißﬂ og et al. 
2001). Bevacizumab-based therapy is associated with signiﬁ cantly improved progres-
sion-free survival (PFS) over chemotherapy alone in patients with advanced or meta-
static NSCLC (Reck et al. 2009; Sandler et al. 2006), the most common form of lung 
cancer. The aim of this analysis was to assess the potential cost savings for Italy 
resulting from a higher number of progression-free metastatic NSCLC patients return-
ing to work while treated with bevacizumab-based therapy. METHODS: Productivity 
losses were calculated on the basis of number of days lost due to illness. Country labor 
costs and employment rates were taken from EUROSTAT. It was assumed, based on 
expert opinion, that 20% of progression-free patients with ECOG performance status 
0–1 and eligible to work would go back to their original employment status after the 
induction therapy. The percentage of PFS patients was calculated from two clinical 
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trials (Reck et al. 2009; Sandler et al. 2006) at two time points from baseline: 12 and 
18 months. PFS percentages were applied to the incidence estimations for metastatic 
NSCLC in Italy. Incidence of nonsquamous metastatic NSCLC was estimated as 37% 
of lung cancer incidence retrieved from GLOBOCAN. Sensitivity analysis was con-
ducted varying the percentage of employment pattern (part time/full time) and the 
labor cost. RESULTS: Bevacizumab-based therapy resulted in mean savings due to 
reduced productivity losses per progression-free patient of c20,089 at 12 months and 
c36,160 at 18 months. Changes in employment patterns, from 60% full time/40% 
part time to 80% full time/20% part time, increased cost savings per patient to 
c22,600 and c40,680 12 and 18 months, respectively. CONCLUSIONS: Bevaci-
zumab-based therapy results in societal cost savings due to improved PFS in metastatic 
NSCLC patients.
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OBJECTIVES: The clinical burden of melanoma patients worsens signiﬁ cantly upon 
metastasis. However, little is known regarding how hospitalization burden changes upon 
metastasis. This study compares the hospitalization burden between metastatic and 
nonmetastatic melanoma patients in a geographically diverse commercially insured US 
population. METHODS: Insurance claims (January 1, 2004–June 30, 2009) from the 
HealthCore Integrated Research Database was used to identify patients aged ≥18 years 
with ≥2 melanoma claims (ICD-9-CM 172.xx, V10.82). Two mutually exclusive cohorts 
were formed: 1) metastatic melanoma (MM) cohort with ≥1 claim for metastasis (ICD-
9-CM 196.x-198.x), and 2) non-MM cohort comprising the remaining patients. The 
ﬁ rst claims for MM and melanoma were the index claims for the respective cohorts. 
Hospitalization burden was compared between the two cohorts based on four outcomes. 
The rate of inpatient visits (per-patient-per-month [PPPM]), and the risk of ﬁ rst hospi-
talization from index claim, were compared using Poisson and Cox-proportional 
hazards regression, respectively. The mean days to ﬁ rst hospitalization and the mean 
length of stay (per-patient-per-month [PPPV] ) were compared using generalized linear 
models. RESULTS: The study included 17,756 (mean age 54.4 years, 49.69% female) 
non-MM patients and 636 (mean age 56.3 years, 41.04% female) MM patients. The 
proportion of patients with ≥1 hospitalization was 2.4 times higher in the MM compared 
to the non-MM cohort (45% vs. 19%, P < 0.01). Compared to the non-MM cohort, 
the MM cohort had: four times higher PPPM inpatient visit rate (0.04 vs. 0.01, P < 
0.001), threefold greater risk of ﬁ rst hospitalization (HR: 3.01; 95% CI: 2.61–3.46), 
and shorter mean days to ﬁ rst hospitalization (35 days vs. 309 days, P < 0.001). The 
mean days of inpatient visit (PPPV) were comparable (3.93 vs. 3.54, P = 0.32). CON-
CLUSIONS: The hospitalization burden in metastatic melanoma patients is signiﬁ cantly 
higher than patients whose melanoma has not progressed to metastasis. Treatments that 
improve progression-free survival may reduce this burden.
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OBJECTIVES: The EPICLIN-Lung study aims to provide information on NSCLC 
clinical management across European countries. As part of this study, information on 
resources associated with the diagnosis of NSCLC from ﬁ rst visit to ﬁ nal diagnosis 
across Europe was collected and described. METHODS: The EPICLIN-Lung study 
(NCT00831909) is a noninterventional prospective cohort study conducted in 
Belgium, France, Germany, Greece, Italy, Portugal, Spain, and Turkey. Patients with 
conﬁ rmed NSCLC attending a participating clinical department for the ﬁ rst time 
between January and March 2009 were included. Information on the approach to 
disease diagnosis was recorded at the ﬁ rst visit. Descriptive analyses were performed. 
RESULTS: A total of 3500 patients were included in the analysis and 2691 (76.9%) 
presented with symptoms at ﬁ rst visit. The mean age (SD) of patients was 64.5 (± 
10.5) years. From ﬁ rst visit to ﬁ nal diagnosis, 3124 (89.3%) patients utilized health-
care resources including radiology (51.5%), general practitioner ofﬁ ce (37.7%), other 
resources (19.3%), oncology (19.0%), surgery (17.9%), emergency room (12.8%), 
drug administration facilities (1.6%), and blood-speciﬁ c resources (0.3%). The appli-
cation of tests for diagnosis occurred in 96.0% of patients and included laboratory 
tests (77.5%), bronchoscopy (73.9%), ﬁ ne needle aspiration biopsy (26.5%), other 
tests (20.5%), and biomarker determination (11.3%). Imaging technology was also 
used in disease assessment with scanning the most frequently used technology (88.7% 
of patients), followed by x-ray (65.9%), MRI/CT brain scan (39.5%), PET imaging 
(34.1%), and other imaging tests (21.5%). CONCLUSIONS: The resource used from 
ﬁ rst visit to ﬁ nal diagnosis of NSCLC is not uniform within the patient demographic 
across Europe. In particular, biomarker determination was low but bronchoscopy and 
laboratory tests were relatively high as was the use of imaging technology. a more 
uniform approach in the use of these resources may improve the impact of current 
treatments. More speciﬁ c results will be presented at the meeting.
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OBJECTIVES: We conducted this study to document the health-care resource utiliza-
tion associated with treatment of patients with advanced melanoma. METHODS: 
MELODY (Melanoma treatment patterns and outcomes among patients with unre-
sectable stage III or stage IV disease: a retrospective longitudinal survey) is an obser-
vational study managed at 31 centers in France, Italy, and the UK. Eligible patients 
had attended at one of the sites with a diagnosis of unresectable stage III or IV mela-
noma between July 1, 2005 and June 30, 2006; data were retrieved from diagnosis 
(no limit date) until 2008. The primary objective was to document the ﬁ rst-line treat-
ments received by patients. Secondary objectives included ascertaining health-care 
resource utilization related to up to three lines of treatment (anticancer and supportive 
care). Data were collected from patients (n = 776) using a case-report form that 
included information on hospitalizations, outpatient visits, hospice care, and adverse-
event management (transfusions and concomitant medications including antiemetics 
and growth factors). Resource use data were collected from patients (n = 606) that 
received systemic treatment outside a clinical trial and/or supportive care. RESULTS: 
Twenty-nine percent (176/606) of patients required medical management for treat-
ment-related adverse events and 32% (195/606) were hospitalized while receiving 
systemic treatment and/or supportive care with 25% of these having at least four 
hospitalizations. The median duration of hospitalization was 17 days, with 25% 
spending at least 29 days in hospital (may comprise multiple stays). The hospitaliza-
tion rate was higher in patients receiving supportive care than those receiving antican-
cer treatment (86/170; 51% vs. 140/553; 25%), but median duration of hospitalization 
was similar (15.0 vs. 14.5 days). Results by line of anticancer therapy and supportive 
care will be presented. CONCLUSIONS: These results from MELODY suggest that 
the systemic and palliative treatments used to manage advanced melanoma are associ-
ated with considerable resource utilization, highlighting the need for more effective 
treatment options.
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OBJECTIVES: To examine the patient characteristics, cancer therapy use, and costs 
among patients with mPC. METHODS: Subjects in the Marketscan Commerical 
Claims and Encounters and Supplemental Medicare databases (July 1, 2004–June 30, 
2008) were included if they received a diagnosis of metastastasis (ICD-9 codes: 
197.x—199.x) on or after the ﬁ rst occurrence of PC (ICD-9 code: 157.x), had no 
claims for other secondary metastases within 6 months of the initial mPC claim (e.g. 
index date), and had continuous insurance coverage from 6 months prior through at 
least 1 month post index. Outpatient cancer therapies and costs are described from 
mPC index until loss to follow-up or end of the data collection period. RESULTS: 
There were 4938 subjects with incident mPC included in the analysis. The mean age 
at index date was 64.8 years (SD = 11.8) and 53.8% were male. Subjects were followed 
an average of 8.3 months post index. Among patients with incident mPC, 53.3% 
received outpatient chemotherapy with gemcitabine (76.4%) being the most com-
monly received therapy. 20.1% of mPC subjects received the targeted agent, erlotinib, 
post-index, with 63.6% of its use occurring in combination with gemcitabine. Subjects 
who received gemcitabine, received an average of 9.5 doses (SD: 8.8) over 108.9 days 
(SD: 129.5). Subjects who received erlotinib, ﬁ lled an average of 3.9 prescriptions (SD: 
4.1) following mPC index. Post-metastases, 84.1% and 73.3% of subjects were hos-
pitalized or visited the ER respectively. The mean cost per month of treating mPC 
subjects was $16,192 (SD = $21,639), with the majority of these costs attributed to 
inpatient stays (57.8%) and outpatient visits (35.0%). Outpatient cancer therapies 
contributed 5.3% of the mean monthly cost post index. CONCLUSIONS: Gem-
citabine was the predominant cancer therapy among subjects with incident mPC. 
Outpatient cancer drugs constituted a small portion of the total mean monthly cost 
of mPC.
